Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 9th Annual Meeting on Immunology and Immunologist Kuala Lumpur, Malaysia.

Day 2 :

  • vaccines and vaccination

Dr Jacques Choucair got his MD degree in 1994 from the Saint-Joseph University, Faculty of Medicine in Beyrouth then his ID subspeciality from Paris VII University, School of Medicine

Since May 2001, he is a practitioner and ID consultant in the Infectious diseases department at Hôtel Dieu de France de Beyrouth teaching hospital.

He published more than 20 articles and is a reviewer in national and international journals. His main topics of interest are bacterial resistance and the proper use of antibiotics.

He is a member in the arab association for the proper use of antibiotics and member of ESCMID.


OBJECTIVE:To assess, in non vaccinated healthy adults, the response to the standard protocol SP of vaccination for hepatitis B (0, 1, 6 months), and the response to two boosters protocols in non-responders (NR).

METHODS:192 adults, mean age of 44.3 receive (Engerix® B 20 µg/1 ml) by the SP. The non-responders (anti-Hbs antibodies <10UI/l) are divided into two groups. The first group (P1) receives a single booster (R1) 4 months after the SP, and those who remained non-responders receive a double booster (R1b) 2 years after the SP. The second group (P2) receives a unique double booster (R2), 2 years after the SP.


The rate of response after the SP is 75.5 %( 145/192).

28 NR in (P1) have a response rate of 32.14 %( 9/28). The 19 NR in (R1b) have a response of 36.84 %( 7/19).

19 NR (P2) have a response of 63.16 %( 12/19).

9.9 %( 19/192) of individuals don't respond to any booster. The rate of response decreases with the age( 5% every year and 41% every 10 years)

For the same age, men are 2 fold more responders then women.

CONCLUSION :A unique double booster done 2 years after the SP gives a better response then a single booster done after 4 months, and a similar response to a single booster done after 4 months followed by a double booster done after 2 years. The female gender and the age are 2 factors that decrease the response to the vaccination.

  • Immunology and Medicine Immunology

Moatasem  still  PhD student at Faculty of Biology, Sultan Idris university, has complete master degree in immunology in faculty biology at Thi-Qar university whith Honors score. He has published more than 11 papers in reputed journals and has been serving as an editorial board member of repute. He has numerous Participations in Scientific  & educational conferences and have  some of awards from journals and conferences.


Objective: This study aimed to determine the level of serum indicators of cellular oxidative stress and the antioxidant the relevance with inflammations parameters, establishing the inflammatory profile in patients with rheumatoid arthritis.

Method:  The sample of the study take in 50 patients with RA. They were confirming the dealings of the 2007 American College of Rheumatology, also the sample of the study include fifty person seemingly healthy volunteers were included in this study. We determined the plasmatic levels of malondialdehyde, compare with the inflammatory parameters such as CRP, ESR, RF, calculation of total WBC and diffraction numerous of WBC. In addition, the phagocytosis processes.

Results: in comparison to controls, patients with rheumatoid arthritis presented high concentrations of lipid peroxidation products (determined by plasmatic levels of malondialdehyde, as well as the study shown high signification between the studied groups according the immunological markers

Conclusion: our results indicate the presence of molecular damage determined by oxygen free radicals in patients with rheumatoid arthritis and this is play main role in immune response of patients.

Key word: C-reactive protein, free radicals ROS, MDA, neutrophil, rheumatoid arthritis.


Ryan Aliñab is a current resident of Internal medicine at Chinese General Hospital Medical Center. He graduated from University of Santo Tomas, Philippines last 2013 with the degree of doctor of medicine. 




Idiopathic systemic capillary leak syndrome (ISCLS) or Clarkson’s disease is an extremely rare and fatal condition characterized by episodic attacks of capillary leakage of plasma from the intravascular to the interstitial space resulting in hypotension, hemoconcentration, and hypoalbuminemia. If not diagnosed early, it has a high morbidity and mortality rate. Treatment is supportive, focusing on aggressive but cautious fluid resuscitation together with pharmacologic treatment to control capillary leakage. Each attack vary in severity and can be life features threatening due possible organ failure secondary to poor perfusion.

This study aims to raise awareness of the main presentation of ISCLS, to explain the possible pathophysiology, clinical course of the disease, to differentiate with other causes of distributive shock and to present the latest recommendations on treatment and prevention based on limited evidences available.

Case presentation

Our case is a 38 year old male who initially experienced flu-like symptoms such as body malaise, headache and generalized weakness. He was previously treated as a case of community-acquired pneumonia, high risk, admitted at the intensive care unit. He claimed to have a history of allergy to seafood and medications such as paracetamol and antibiotics. At the emergency room, patient was hypotensive and was managed as a case of anaphylactic shock. He was hydrated, started on inotropic agents and corticosteroid. Work-up tests revealed severe hemoconcentration, hypoalbuminemia, metabolic acidosis, and hyperkalemia. No focus of infection was documented. He remained stable with negative fluid balance until the fourth hospital day, when he suddenly developed pulmonary edema. Patient was managed with diuretics, airway support and inotropics. Patient condition improved and was discharged on 10th hospital day.


ISCLS is a rare and fatal disease that has a high mortality if not detected early. Therefore, prompt recognition is important in the effective management of the disease and its complications.




  • Adaptive Immune response

Dr. BenMohamed is a Professor of Immunology, the founder and the head of the Laboratory of Cellular and Molecular Immunology at the University of California. He also holds a joint appointment with UC Irvine Institute of Immunology and with UC Irvine Chao Family Comprehensive Cancer Center.Dr. BenMohamed received his Ph.D. in Immunology from the Pasteur Institute, Paris, France in 1997 where he worked as the key developer and co-inventor of a new promising vaccine strategy that uses mucosal delivery of clinically approved lipopeptide molecules



Herpes simplex virus type 1 (HSV-1) is a prevalent human pathogen that infects over 3.72 billion individuals worldwide and can cause potentially blinding recurrent corneal herpetic disease. HSV-1 establishes latency within sensory neurons of trigeminal ganglia (TG) and TG-resident CD8+ T cells play a critical role in preventing its reactivation. The repertoire, phenotype and function of protective CD8+ T cells are unknown. Bolstering the apparent feeble numbers of CD8+ T cells in TG remains a challenge for immunotherapeutic strategies. In this study, a comprehensive panel of 467 HLA-A*0201-restricted CD8+ T cell epitopes were predicted from the entire HSV-1 genome. CD8+ T cell responses to these genome-wide epitopes were compared in HSV-1 seropositive symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent herpetic disease) vs. asymptomatic (ASYMP) individuals (who are infected but never experienced any recurrent herpetic disease). Frequent polyfunctional HSV-specific effector memory IFN-g+CD107a/b+CD44highCD62LlowCD8+ TEM cells were detected in ASYMP individuals and were mainly directed against three “ASYMP” epitopes. In contrast, SYMP individuals have more mono-functional central memory CD44highCD62LhighCD8+ TCM cells. Furthermore, therapeutic immunization with an innovative prime/pull vaccine, based on priming with multiple “ASYMP” epitopes (prime) and neurotropic TG delivery of the T-cell attracting chemokine CXCL-10 (pull), boosted the number and function of CD44highCD62LlowCD8+ TEM and tissue-resident CD103highCD8+ TRM cells in TG of latently infected HLA-A*0201 Tg mice and reduced recurrent ocular herpes following UV-B induced reactivation. These findings have profound implications in the development of T-cell-based immunotherapeutic strategies to treat blinding recurrent herpes infection and disease. 

  • Immunology

Dr. Neeraj Mishra is working as Associate Professor in Department of Pharmaceutics at ISF College of Pharmacy, Moga (Punjab) since July 2012. He has completed his B. Pharm (2000), M. Pharm (2003) and Ph.D. (2011) in Pharmaceutical Sciences from Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, Sagar (M.P.). He is having 38 International and 14 National Publication typically in recent concept of novel drug delivery system, particularly in vaccine delivery and drug targeting. He is also written 4 book chapter in national and International publisher (Nova Science Publishers).



Mucosal immunization frequently results in the stimulation of both mucosal and systemic immune responses, whereas systemic immunization typically induces systemic responses without activating the mucosal immune system. The present study was aimed at exploring the targeting potential of LTA-anchored chitosan nanoparticles (CH-NP) specifi cally to M cell following oral immunization. The lectinized CH-NP exhibited 7 – 29% coupling capacity depending upon the amount of glutaraldehyde added. Induction of the mucosal immunity was assessed by estimating secretory IgA level in the salivary, intestinal and vaginal secretions, and cytokine (IL-2 and IFN- g) levels in the spleen homogenates. The results demonstrated that LTAanchored CHNP elicited strong humoral and cellular responses and hence could be a competent carrier-adjuvant deliverysystem for oral mucosal immunization against Hepatitis B.

Key Words: chitosan nanoparticles , hepatitis B , LTA lectin , M cells , oral immunization